BRIACELL THERAPEUTICS CORPORATION

Blood Test Monitoring PD-L1 Expression Shows Promise for Improving Immunotherapy Outcomes in Metastatic Breast Cancer

- Clinical trials demonstrate that the LifeTracDx® blood test can monitor PD-L1 upregulation in metastatic breast cancer patients, with 76% showing increased expression after leronlimab treatment. - Four-year survival data reveals that 5 patients with PD-L1 upregulation detected by blood test and subsequently treated with checkpoint inhibitors remained alive after four years. - The blood test technology captures both circulating tumor cells and Cancer Associated Macrophage-Like cells to provide real-time monitoring of tumor response and companion diagnostics. - Separate studies show the approach can predict treatment response within 30 days and guide combination therapy decisions for metastatic breast cancer patients.